Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to $900000.0.

  • Bio-Techne's Gains from Investment Securities fell 1000.0% to $900000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $900000.0, marking a year-over-year increase of 10080.5%. This contributed to the annual value of $9.5 million for FY2025, which is 1830.04% down from last year.
  • Latest data reveals that Bio-Techne reported Gains from Investment Securities of $900000.0 as of Q4 2025, which was down 1000.0% from $900000.0 recorded in Q3 2025.
  • In the past 5 years, Bio-Techne's Gains from Investment Securities registered a high of $122.8 million during Q3 2021, and its lowest value of -$141.8 million during Q2 2023.
  • Its 5-year average for Gains from Investment Securities is $6.0 million, with a median of $1.1 million in 2024.
  • In the last 5 years, Bio-Techne's Gains from Investment Securities surged by 77142.86% in 2021 and then plummeted by 119076.92% in 2023.
  • Quarter analysis of 5 years shows Bio-Techne's Gains from Investment Securities stood at $6.1 million in 2021, then crashed by 85.25% to $900000.0 in 2022, then surged by 44.44% to $1.3 million in 2023, then decreased by 23.08% to $1.0 million in 2024, then decreased by 10.0% to $900000.0 in 2025.
  • Its last three reported values are $900000.0 in Q4 2025, $900000.0 for Q3 2025, and $1.2 million during Q2 2025.